Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif

Journal of Molecular Biology

Volumn 410, Issue 5, 2011, Pages 1065-1076

  Britan Rosich, Elena ^a   Nowarski, Roni ^a   Kotler, Moshe ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

deaminase; enzyme kinetics; innate immunity; peptides; virion

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; DEAMINASE; VIF PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; DAUDI CELL; DEAMINATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; INNATE IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRION; VIRUS PARTICLE; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79960380329     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2011.03.058     Document Type: Article

References (82)

1. Jarmuz A.; Chester A.; Bayliss J.; Gisbourne J.; Dunham I.; Scott J.; and Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22 Genomics 79 2002 285 296 (Pubitemid 34211936)
2. Wedekind J.E.; Dance G.S.; Sowden M.P.; and Smith H.C. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business Trends Genet. 19 2003 207 216 (Pubitemid 36398423)
3. Conticello S.G.; Thomas C.J.; Petersen-Mahrt S.K.; and Neuberger M.S. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases Mol. Biol. Evol. 22 2005 367 377 (Pubitemid 40130201)
4. Muramatsu M.; Sankaranand V.S.; Anant S.; Sugai M.; Kinoshita K.; Davidson N.O.; and Honjo T. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells J. Biol. Chem. 274 1999 18470 18476
5. Muramatsu M.; Kinoshita K.; Fagarasan S.; Yamada S.; Shinkai Y.; and Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme Cell 102 2000 553 563
6. Liao W.; Hong S.H.; Chan B.H.; Rudolph F.B.; Clark S.C.; and Chan L. APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family Biochem. Biophys. Res. Commun. 260 1999 398 404 (Pubitemid 29352076)
7. Etard C.; Roostalu U.; and Strahle U. Lack of Apobec2-related proteins causes a dystrophic muscle phenotype in zebrafish embryos J. Cell Biol. 189 2010 527 539
8. Sato Y.; Probst H.C.; Tatsumi R.; Ikeuchi Y.; Neuberger M.S.; and Rada C. Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy J. Biol. Chem. 285 2010 7111 7118
9. Reizer J.; Buskirk S.; Bairoch A.; Reizer A.; and Saier M.H. Jr A novel zinc-binding motif found in two ubiquitous deaminase families Protein Sci. 3 1994 853 856 (Pubitemid 24139911)
10. Iwatani Y.; Takeuchi H.; Strebel K.; and Levin J.G. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect J. Virol. 80 2006 5992 6002 (Pubitemid 43849177)
11. Langlois M.A.; Beale R.C.; Conticello S.G.; and Neuberger M.S. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities Nucleic Acids Res. 33 2005 1913 1923 (Pubitemid 41748336)
12. Hache G.; Liddament M.T.; and Harris R.S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain J. Biol. Chem. 280 2005 10920 10924 (Pubitemid 40418393)
13. Hakata Y.; and Landau N.R. Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains J. Biol. Chem. 281 2006 36624 36631 (Pubitemid 46042129)
14. Jonsson S.R.; Hache G.; Stenglein M.D.; Fahrenkrug S.C.; Andresdottir V.; and Harris R.S. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins Nucleic Acids Res. 34 2006 5683 5694 (Pubitemid 44742455)
15. Navarro F.; Bollman B.; Chen H.; Konig R.; Yu Q.; Chiles K.; and Landau N.R. Complementary function of the two catalytic domains of APOBEC3G Virology 333 2005 374 386 (Pubitemid 40250119)
16. Newman E.N.; Holmes R.K.; Craig H.M.; Klein K.C.; Lingappa J.R.; Malim M.H.; and Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity Curr. Biol. 15 2005 166 170
17. Opi S.; Takeuchi H.; Kao S.; Khan M.A.; Miyagi E.; and Goila-Gaur R. Monomeric APOBEC3G is catalytically active and has antiviral activity J. Virol. 80 2006 4673 4682
18. Esnault C.; Heidmann O.; Delebecque F.; Dewannieux M.; Ribet D.; and Hance A.J. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses Nature 433 2005 430 433 (Pubitemid 40203324)
19. Esnault C.; Millet J.; Schwartz O.; and Heidmann T. Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses Nucleic Acids Res. 34 2006 1522 1531
20. Schumacher A.J.; Nissley D.V.; and Harris R.S. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast Proc. Natl Acad. Sci. USA 102 2005 9854 9859 (Pubitemid 40993657)
21. Chiu Y.L.; Witkowska H.E.; Hall S.C.; Santiago M.; Soros V.B.; and Esnault C. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition Proc. Natl Acad. Sci. USA 103 2006 15588 15593 (Pubitemid 44625636)
22. Hulme A.E.; Bogerd H.P.; Cullen B.R.; and Moran J.V. Selective inhibition of Alu retrotransposition by APOBEC3G Gene 390 2007 199 205 (Pubitemid 46241746)
23. Lecossier D.; Bouchonnet F.; Clavel F.; and Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein Science 300 2003 1112 (Pubitemid 36583087)
24. Mangeat B.; Turelli P.; Caron G.; Friedli M.; Perrin L.; and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts Nature 424 2003 99 103 (Pubitemid 36834849)
25. Mariani R.; Chen D.; Schrofelbauer B.; Navarro F.; Konig R.; and Bollman B. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif Cell 114 2003 21 31 (Pubitemid 36859838)
26. Zhang H.; Yang B.; Pomerantz R.J.; Zhang C.; Arunachalam S.C.; and Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA Nature 424 2003 94 98 (Pubitemid 36834848)
27. Harris R.S.; Bishop K.N.; Sheehy A.M.; Craig H.M.; Petersen-Mahrt S.K.; and Watt I.N. DNA deamination mediates innate immunity to retroviral infection Cell 113 2003 803 809 (Pubitemid 36724943)
28. Beale R.C.; Petersen-Mahrt S.K.; Watt I.N.; Harris R.S.; Rada C.; and Neuberger M.S. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo J. Mol. Biol. 337 2004 585 596 (Pubitemid 38326879)
29. Suspene R.; Sommer P.; Henry M.; Ferris S.; Guetard D.; and Pochet S. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase Nucleic Acids Res. 32 2004 2421 2429 (Pubitemid 38854796)
30. Luo K.; Xiao Z.; Ehrlich E.; Yu Y.; Liu B.; Zheng S.; and Yu X.F. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G Proc. Natl Acad. Sci. USA 102 2005 11444 11449 (Pubitemid 41153839)
31. Conticello S.G.; Harris R.S.; and Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G Curr. Biol. 13 2003 2009 2013 (Pubitemid 37425213)
32. Kao S.; Khan M.A.; Miyagi E.; Plishka R.; Buckler-White A.; and Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity J. Virol. 77 2003 11398 11407 (Pubitemid 37271638)
33. Marin M.; Rose K.M.; Kozak S.L.; and Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation Nat. Med. 9 2003 1398 1403 (Pubitemid 37466189)
34. Mehle A.; Strack B.; Ancuta P.; Zhang C.; McPike M.; and Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway J. Biol. Chem. 279 2004 7792 7798 (Pubitemid 38294663)
35. Nowarski R.; Britan-Rosich E.; Shiloach T.; and Kotler M. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase Nat. Struct. Mol. Biol. 15 2008 1059 1066
36. Borman A.M.; Quillent C.; Charneau P.; Kean K.M.; and Clavel F. A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G → A hypermutation during negative-strand viral DNA synthesis Virology 208 1995 601 609
37. Gifford R.J.; Rhee S.Y.; Eriksson N.; Liu T.F.; Kiuchi M.; Das A.K.; and Shafer R.W. Sequence editing by apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance Aids 22 2008 717 725 (Pubitemid 351450640)
38. Janini M.; Rogers M.; Birx D.R.; and McCutchan F.E. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells J. Virol. 75 2001 7973 7986 (Pubitemid 32743669)
39. Vartanian J.P.; Meyerhans A.; Asjo B.; and Wain-Hobson S. Selection, recombination, and G → A hypermutation of human immunodeficiency virus type 1 genomes J. Virol. 65 1991 1779 1788
40. Rangel H.R.; Garzaro D.; Rodriguez A.K.; Ramirez A.H.; Ameli G.; Del Rosario Gutierrez C.; and Pujol F.H. Deletion, insertion and stop codon mutations in vif genes of HIV-1 infecting slow progressor patients J. Infect. Dev. Ctries. 3 2009 531 538
41. Sato K.; Izumi T.; Misawa N.; Kobayashi T.; Yamashita Y.; and Ohmichi M. Remarkable lethal G-to-A mutations in Vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice J. Virol. 84 2010 9546 9556
42. Kim E.Y.; Bhattacharya T.; Kunstman K.; Swantek P.; Koning F.A.; Malim M.H.; and Wolinsky S.M. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure J. Virol. 84 2010 10402 10405
43. Sadler H.A.; Stenglein M.D.; Harris R.S.; and Mansky L.M. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis J. Virol. 84 2010 7396 7404
44. Hultquist J.F.; and Harris R.S. Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS Future Virol. 4 2009 605
45. Mulder L.C.; Harari A.; and Simon V. Cytidine deamination induced HIV-1 drug resistance Proc. Natl Acad. Sci. USA 105 2008 5501 5506 (Pubitemid 351753892)
46. Pillai S.K.; Wong J.K.; and Barbour J.D. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3) Retrovirology 5 2008 26
47. Camaur D.; and Trono D. Characterization of human immunodeficiency virus type 1 Vif particle incorporation J. Virol. 70 1996 6106 6111 (Pubitemid 26266826)
48. Kao S.; Akari H.; Khan M.A.; Dettenhofer M.; Yu X.F.; and Strebel K. Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection J. Virol. 77 2003 1131 1140 (Pubitemid 36055535)
49. Santa-Marta M.; da Silva F.A.; Fonseca A.M.; and Goncalves J. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation J. Biol. Chem. 280 2005 8765 8775 (Pubitemid 40409564)
50. Santa-Marta M.; Aires da Silva F.; Fonseca A.M.; Rato S.; and Goncalves J. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action Mol. Immunol. 44 2007 583 590 (Pubitemid 44287042)
51. Bogerd H.P.; Doehle B.P.; Wiegand H.L.; and Cullen B.R. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor Proc. Natl Acad. Sci. USA 101 2004 3770 3774 (Pubitemid 38381053)
52. Mangeat B.; Turelli P.; Liao S.; and Trono D. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action J. Biol. Chem. 279 2004 14481 14483 (Pubitemid 38618833)
53. Schrofelbauer B.; Chen D.; and Landau N.R. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif) Proc. Natl Acad. Sci. USA 101 2004 3927 3932 (Pubitemid 38381079)
54. Xu H.; Svarovskaia E.S.; Barr R.; Zhang Y.; Khan M.A.; Strebel K.; and Pathak V.K. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion Proc. Natl Acad. Sci. USA 101 2004 5652 5657 (Pubitemid 38481211)
55. Mehle A.; Thomas E.R.; Rajendran K.S.; and Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection J. Biol. Chem. 281 2006 17259 17265
56. Kao S.; Goila-Gaur R.; Miyagi E.; Khan M.A.; Opi S.; Takeuchi H.; and Strebel K. Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif Virology 369 2007 329 339 (Pubitemid 350087192)
57. Kao S.; Miyagi E.; Khan M.A.; Takeuchi H.; Opi S.; Goila-Gaur R.; and Strebel K. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells Retrovirology 1 2004 27
58. Carr J.M.; Davis A.J.; Coolen C.; Cheney K.; Burrell C.J.; and Li P. Vif-deficient HIV reverse transcription complexes (RTCs) are subject to structural changes and mutation of RTC-associated reverse transcription products Virology 351 2006 80 91 (Pubitemid 44056064)
59. Yamashita T.; Nomaguchi M.; Miyake A.; Uchiyama T.; and Adachi A. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity Microbes Infect. 12 2010 166 171
60. Stopak K.; de Noronha C.; Yonemoto W.; and Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability Mol. Cell 12 2003 591 601 (Pubitemid 37222482)
61. Yu X.; Yu Y.; Liu B.; Luo K.; Kong W.; Mao P.; and Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex Science 302 2003 1056 1060 (Pubitemid 37386201)
62. Liu H.; Wu X.; Newman M.; Shaw G.M.; Hahn B.H.; and Kappes J.C. The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures J. Virol. 69 1995 7630 7638
63. Dettenhofer M.; and Yu X.F. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions J. Virol. 73 1999 1460 1467 (Pubitemid 29036802)
64. Simon J.H.; Miller D.L.; Fouchier R.A.; and Malim M.H. Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function Virology 248 1998 182 187 (Pubitemid 28417705)
65. Iwatani Y.; Chan D.S.; Liu L.; Yoshii H.; Shibata J.; and Yamamoto N. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain Proc. Natl Acad. Sci. USA 106 2009 19539 19544
66. Green L.A.; Liu Y.; and He J.J. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy J. Biol. Chem. 284 2009 13363 13372
67. Ao Z.; Yu Z.; Wang L.; Zheng Y.; and Yao X. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection PLoS One 3 2008 e1995
68. Reingewertz T.H.; Benyamini H.; Lebendiker M.; Shalev D.E.; and Friedler A. The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state Protein Eng. Des. Sel. 22 2009 281 287
69. Reingewertz T.H.; Shalev D.E.; and Friedler A. Structural disorder in the HIV-1 Vif protein and interaction-dependent gain of structure Protein Pept. Lett. 17 2010 988 998
70. Auclair J.R.; Green K.M.; Shandilya S.; Evans J.E.; Somasundaran M.; and Schiffer C.A. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity Proteins 69 2007 270 284 (Pubitemid 47429290)
71. Bernacchi S.; Henriet S.; Dumas P.; Paillart J.C.; and Marquet R. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study J. Biol. Chem. 282 2007 26361 26368 (Pubitemid 47443766)
72. Oberste M.S.; and Gonda M.A. Conservation of amino-acid sequence motifs in lentivirus Vif proteins Virus Genes 6 1992 95 102
73. Goncalves J.; Jallepalli P.; and Gabuzda D.H. Subcellular localization of the Vif protein of human immunodeficiency virus type 1 J. Virol. 68 1994 704 712 (Pubitemid 24022172)
74. Simon J.H.; Sheehy A.M.; Carpenter E.A.; Fouchier R.A.; and Malim M.H. Mutational analysis of the human immunodeficiency virus type 1 Vif protein J. Virol. 73 1999 2675 2681 (Pubitemid 29135652)
75. Tian C.; Yu X.; Zhang W.; Wang T.; Xu R.; and Yu X.F. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F J. Virol. 80 2006 3112 3115 (Pubitemid 43346410)
76. Khamsri B.; Fujita M.; Kamada K.; Piroozmand A.; Yamashita T.; Uchiyama T.; and Adachi A. Effects of lysine to arginine mutations in HIV-1 Vif on its expression and viral infectivity Int. J. Mol. Med. 18 2006 679 683
77. Xiao Z.; Ehrlich E.; Yu Y.; Luo K.; Wang T.; Tian C.; and Yu X.F. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif Virology 349 2006 290 299 (Pubitemid 43782879)
78. Browne E.P.; Allers C.; and Landau N.R. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent Virology 387 2009 313 321
79. Ratner L.; Haseltine W.; Patarca R.; Livak K.J.; Starcich B.; and Josephs Complete nucleotide sequence of the AIDS virus, HTLV-III Nature 313 1985 277 284 (Pubitemid 15151982)
80. Yang X.; Goncalves J.; and Gabuzda D. Phosphorylation of Vif and its role in HIV-1 replication J. Biol. Chem. 271 1996 10121 10129 (Pubitemid 26131573)
81. Kimpton J.; and Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene J. Virol. 66 1992 2232 2239
82. Chesebro B.; Wehrly K.; Nishio J.; and Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism J. Virol. 66 1992 6547 6554